ClinVar Miner

Submissions for variant NM_000016.6(ACADM):c.346T>G (p.Cys116Gly)

dbSNP: rs875989863
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000211478 SCV000268461 uncertain significance Medium-chain acyl-coenzyme A dehydrogenase deficiency 2015-02-20 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000758716 SCV000887492 uncertain significance not provided 2018-01-18 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000211478 SCV001399345 likely pathogenic Medium-chain acyl-coenzyme A dehydrogenase deficiency 2024-01-03 criteria provided, single submitter clinical testing This sequence change replaces cysteine, which is neutral and slightly polar, with glycine, which is neutral and non-polar, at codon 116 of the ACADM protein (p.Cys116Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with medium-chain acyl-coenzyme A dehydrogenase deficiency (PMID: 20434380). ClinVar contains an entry for this variant (Variation ID: 226076). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACADM protein function with a positive predictive value of 80%. Studies have shown that this missense change is associated with inconclusive levels of altered splicing (PMID: 34923709). This variant disrupts the p.Cys116 amino acid residue in ACADM. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9158144, 19649258, 20567907, 29285339). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Revvity Omics, Revvity RCV000211478 SCV003826889 likely pathogenic Medium-chain acyl-coenzyme A dehydrogenase deficiency 2022-05-30 criteria provided, single submitter clinical testing
Baylor Genetics RCV000211478 SCV005053012 likely pathogenic Medium-chain acyl-coenzyme A dehydrogenase deficiency 2024-02-07 criteria provided, single submitter clinical testing
Natera, Inc. RCV000211478 SCV001460424 uncertain significance Medium-chain acyl-coenzyme A dehydrogenase deficiency 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.